CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 82.67% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money
2.5389
6.94%
  • Summary
  • Historical Data
Trading сonditions
Spread 0.0322
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.024346 %
Charges from full value of position ($-4.63)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.024346%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.002124 %
Charges from full value of position ($0.40)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.002124%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 2.7389
Open 2.7489
1-Year Change -86.59%
Day's Range 2.5489 - 2.7489
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 17, 2024 2.7389 0.0900 3.40% 2.6489 2.7589 2.5989
Dec 16, 2024 2.6989 -0.0300 -1.10% 2.7289 2.7789 2.6189
Dec 13, 2024 2.8089 -0.1200 -4.10% 2.9289 2.9489 2.7389
Dec 12, 2024 2.9289 -0.0800 -2.66% 3.0089 3.1189 2.9089
Dec 11, 2024 3.0489 0.1900 6.65% 2.8589 3.0689 2.7389
Dec 10, 2024 2.8489 -0.2200 -7.17% 3.0689 3.0889 2.7589
Dec 9, 2024 3.0989 -0.2000 -6.06% 3.2989 3.3189 3.0889
Dec 6, 2024 3.2789 0.0300 0.92% 3.2489 3.3289 3.1889
Dec 5, 2024 3.2389 -0.1000 -2.99% 3.3389 3.3889 3.1189
Dec 4, 2024 3.4889 -0.2100 -5.68% 3.6989 3.7089 3.3189
Dec 3, 2024 3.5289 -0.5900 -14.32% 4.1189 4.1789 3.3489
Dec 2, 2024 4.0989 -0.9400 -18.65% 5.0389 5.4289 3.8989
Nov 29, 2024 3.8089 0.0400 1.06% 3.7689 4.5589 3.5989
Nov 27, 2024 2.9889 0.4200 16.35% 2.5689 3.0189 2.4689
Nov 26, 2024 2.3989 -0.1100 -4.38% 2.5089 2.8789 2.3589
Nov 25, 2024 2.2789 0.3500 18.15% 1.9289 2.4689 1.8889
Nov 22, 2024 1.8689 -0.0400 -2.10% 1.9089 1.9789 1.7989
Nov 21, 2024 1.8589 -0.3800 -16.97% 2.2389 2.2689 1.7489
Nov 20, 2024 2.2389 -0.2900 -11.47% 2.5289 2.5789 2.1689
Nov 19, 2024 2.5289 -0.1000 -3.80% 2.6289 2.7089 2.3989

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 3:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Cabaletta Bio, Inc. Company profile

About Cabaletta Bio Inc

Cabaletta Bio Inc. is a clinical-stage biotechnology company. The Company is focused on discovery and development of engineered T-cell therapies for B cell-mediated autoimmune diseases. The T cells are designed to selectively bind and eliminate B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. The Company's lead CAAR T cell product candidate is designed based on chimeric antigen receptor (CAR), and its T cell technology has been developed and is marketed for the treatment of B cell cancers. The Company has discovered and developed four product candidates, including its lead product candidate, to potentially treat patients with mucosal pemphigus vulgaris (mPV), and three additional product candidates that have demonstrated specific and selective target engagement in vitro. Its product pipelines include DSG3-CAART, DSG3/1-CAART, Musk-CAART and FVIII-CAART.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Cabaletta Bio Inc revenues was not reported. Net loss increased 39% to $46.3M. Higher net loss reflects Research and development increase of 53% to $29.7M (expense), Stock-based Compensation in R&D increase of 38% to $2.7M (expense), General and administrative increase of 7% to $10.8M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$1.44 to -$1.80.

Industry: Bio Therapeutic Drugs

2929 Arch Street
Suite 600
PHILADELPHIA
PENNSYLVANIA 19104
US

People also watch

ETH/USD

3,869.41 Price
-1.670% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 1.75

BTC/USD

104,210.30 Price
-2.280% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 50.00

Gold

2,636.12 Price
-0.410% 1D Chg, %
Long position overnight fee -0.0083%
Short position overnight fee 0.0001%
Overnight fee time 22:00 (UTC)
Spread 0.30

US100

21,988.50 Price
+0.050% 1D Chg, %
Long position overnight fee -0.0243%
Short position overnight fee 0.0021%
Overnight fee time 22:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 660,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading